Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Avantor AVTR in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 8 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.55, a high estimate of $28.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 9.11% increase from the previous average price target of $22.50.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Avantor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Cooper | Raymond James | Raises | Outperform | $26.00 | $22.50 |
| Conor McNamara | RBC Capital | Maintains | Outperform | $28.00 | - |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $26.00 | $19.50 |
| Justin Bowers | Deutsche Bank | Raises | Hold | $22.00 | $20.00 |
| Luke Sergott | Barclays | Raises | Overweight | $24.00 | $21.00 |
| Dan Brennan | TD Cowen | Announces | Outperform | $28.00 | - |
| Matthew Sykes | Goldman Sachs | Raises | Buy | $26.00 | $23.00 |
| Tejas Savant | Morgan Stanley | Lowers | Overweight | $22.00 | $24.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $21.00 | $25.00 |
| Andrew Cooper | Raymond James | Lowers | Outperform | $22.50 | $25.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Avantor. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Avantor compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Avantor's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Avantor's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Avantor analyst ratings.
Get to Know Avantor Better
Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.
Avantor's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Avantor faced challenges, resulting in a decline of approximately -7.34% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Avantor's ROE stands out, surpassing industry averages. With an impressive ROE of 2.14%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Avantor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.84%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.1, caution is advised due to increased financial risk.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
